Biotechnology Research in Poland

Pro-Environment Polska Sp. Z O.O

Firma Pro-Environment Polska jest dystrybutorem PerkinElmer Inc – wiodącego dostawcy aparatury analitycznej i badawczej, oraz akcesoriów i materiałów dla branży chemicznej, farmaceutycznej, biotechnologicznej, jakości żywności i ochrony środowiska. Kontynuując doświadczenie PerkinElmer, zaczerpnęliśmy to, co najlepsze z globalnej marki, by tworzyć dopasowane, nowoczesne rozwiązania analityczne dla polskich laboratoriów. Portfolio firmy obejmuje kompleksowe wyposażenie laboratoriów „pod klucz” a także wsparcie aplikacyjne oraz szkolenia i warsztaty dla użytkowników aparatury. Pasjonuje nas analityka, dlatego utworzyliśmy własne laboratorium badawczo-rozwojowe, w którym prowadzimy prace nad innowacyjnymi produktami związanymi z bezpieczeństwem żywności

11 to 50 staff

Ai Ablations Sp. Z O.O

Nowadays we are facing the increasing number of atrial arrhythmias in general population and observe higher number of patients after invasive electrophysiological procedures or cardiac surgeries, which increase the risk of new atrial arrhythmias. Complex atrial arrhythmias like atypical atrial flutter and atrial tachycardia remain challenging for the majority of electrophysiologist. Base on these facts we decided to create the software, which helps electrophysiologist in decision making through patients with complex atrial arrhythmias. Our software use intracardiac electrograms and electroanatomic maps, so the parameters which are routinely use during the ablation procedure

1 to 10 staff

Alab Bioscience

ALAB bioscience is one of the laboratories from the ALAB Group, that provides wide research offer for the Life Science industry. Activities of ALAB bioscience focus on five main areas: laboratory animal health reports (FELASA), scientific and preclinical animal research, human research and clinical research, cell culture and molecular analysis, and microbiome research.

11 to 50 staff

Bacteromic

BacterOMIC has been accelerated in the Scope Fluidics Group. The company develops technological projects for medical diagnostics and healthcare. The strategic goal of the Group is to generate profits as a result of sales of independently developed technology projects for global manufacturers of medical devices. The Scope Fluidics Group provides developed projects with financing, access to laboratories and workshops, and crucial administrative facilities and services. BacterOMIC is the first system to offer full and actionable information for precision antibiotics therapies. BacterOMIC problems all clinically relevant antibiotics in single test. BacterOMIC is also the first system to offer automated testing of multiple antibiotic combinations.

11 to 50 staff

Biofunding Institute

Platforma BFI (Bio Funding Institute) to miejsce łączące międzynarodowe koncerny badawcze z dynamicznie rozwijającymi się podmiotami z branży biotechnologicznej. Dzięki BFI otrzymujesz dostęp do największych przetargów światowych koncernów farmaceutycznych i biotechnologicznych, które pozwolą na rozwój Twojego biznesu. Twoja firma może zyskać przede wszystkim dodatkowe źródło finansowania do rozpoczęcia nowych projektów o wartości od 2 do nawet 130 mln USD oraz bezcenne doświadczenie i relacje biznesowe, które zaprocentują w bliższej i dalszej przyszłości.

1 to 10 staff

Biomedycyna Polska S.A

BiomedycynaPolska S. A. is at the helm of a corporate group of Polish biotechnological companies that specialize in and develop technologies for separation and purification of active pharmaceutical ingredients (API), veterinary medicines as well as dietary supplements. Thanks to holding 100% of the shares of the other group members, the company can offer an integrated business model, starting from development of new technologies, encompassing the entire development path and ending with sale of the product, including proprietary medicinal products. Biomedycyna Polska S. A. invests into development of innovative pharmaceuticals and APIs for treatment and prevention of the main lifestyle diseases e.g. immune system disorders, autoimmunological diseases, communicable diseases and cancers. Biomedycyna Polska S. A. maintains a strong research and development division, which allows for creation of brand-new solutions in the form of applications for innovative API production processes and innovative product solutions.

11 to 50 staff

Biotigen

We specialise in the research and development of Colostrum Bovinum. We supply COLOSTRUM of the highest quality to the global human and animal health markets, with certified production in Poland (EU). Using our extensive knowledge of the unique properties derived from colostrum, we want to make a significant difference to the health and quality of life of people and animals. We want to combine research, technology and knowledge to develop products that can prevent diseases, reduce their side effects or postpone the need for medication. We want to strengthen health with the motto: Natural help for a healthy gut.

1 to 10 staff

Celvet

CelVet is a completely Polish company conducting research on innovative veterinary drugs. We work with research centers in Poland, including with Medical Universities, to develop a new form of oral medicine for animals like cats and dogs. The company also provides consultancy services in the registration and distribution of animal medicines.

1 to 10 staff

Cofactor

COFACTOR is a technology startup, established to conduct scientific research and development activities in the field of biotechnology, founded in 2017, whose mission is to create technology in the field of innovative food, cosmetics and medical applications. The company specializes in research and development activities in the field of manufacturing and commercialization of nutraceutics, cosmeceuticals, pharmaceuticals, and analytical reagents. The main goal and priority of the COFACTOR company is to care for the safety and quality of manufactured substances. Meeting high product quality standards is ensured at every stage: from its development, through production and storage. The effectiveness of all activities is confirmed by maintaining and improving the Management System compliant with national, European and global requirements – ISO 22716 GMP and HACCP. The main research infrastructure of COFACTOR from the beginning of its existence is the Wielkopolska Centre for Advanced Technologies located in Poznan, which is a multidisciplinary center bringing together best specialists in exact sciences, life sciences and technical sciences, focused on new materials and biomaterials with multilateral applications.

1 to 10 staff

Europejskie Centrum Sekwencjonowania

Europejskie Centrum Sekwencjonowania is a company based out of Ul. Jutrzenki 12a, Warszawa, Województwo Mazowieckie, Poland.

11 to 50 staff

Famicord Group Cell And Gene Manufacturing

amiCord Group cord blood banks have been operating in Europe since 2002. They were grouped in a network in 2006 by Polish Stem Cell Bank (PBKM). Since that time FamiCord Group has been developing internationally and become the largest cord blood bank in Europe and the fifth-largest cord blood bank in the World. With a wide range of expertise in cell banking & experience in developing our own ATMP cell therapy product, we are offering our diverse cell therapy expertise to assist with contract manufacturing of autologous, allogeneic and viral vector-based products with total flexibility catering to our client needs. Our dedicated core team has experience working with a wide range of technologies working on cell therapies at different scales and stages to cover requirements. Our facility's flexibility allows us to adapt our facility for client requirements, quality systems in place and EMA regulatory approval allowing us to produce ATMP material for clinical demands offering an end-to-end CDMO service. FamiCord continues to expand its GMP manufacturing capacity to support therapeutic advancement throughout Europe.

201 to 500 staff

Finepharm Sp. Z O.O

11 to 50 staff

Heart Guard

The Heart Guard technology is a system for continual measurement of cardiac metabolism. Heart Guard is designed to support controlled cardiac arrest (cardioplegic arrest) during heart surgery. Heart Guard has the potential to reduce mortality and the rate of severe complications resulting from a suboptimal cardioplegia effect on the cellular level. Proof of principle is confirmed and the term sheet with the first investor has been signed.

1 to 10 staff

Heart Sense

Heart Sense is a team led by dr Grzegorz Suwalski, which has set itself the goal of increasing the effectiveness and safety of coronary artery bypass surgery - this is the most commonly performed cardiac surgery in the world - in 2016, a total of The team is developing an innovative device recording electrocardiographic (ECG) signal directly from the surface of the beating heart. Scientific data and clinical practice indicate that the introduction of such a device will bring benefits to patients (reduction in the number of complications), doctors (facilitation of surgery) and will be more economical (less invasive and cheaper operations). The electrode, which is a key element of the device, will have the form of a "petal" having the ability to connect to the surface of the heart. It will be produced in technology enabling the production of cheap, single-use items.

1 to 10 staff

Isokor

51 to 200 staff

Madbiotech Inc

MadBiotech’s model is based on a developing no-waste and self-sufficient system for the F&B industry. The current model stems from knowledge and skillsets already within the consortium and new knowledge from results obtained by present and/or future research projects. The established partnerships within the consortium are composed of universities, municipalities, NGO’s and partner companies. The wide knowledge base of the group paired with the unique skillsets from each level of organization should provide accurate results that can be tested by MadBiotech and its partners. This approach can evaluate a results potential for scaling and determine the next course of actions. Once the technology and/or methods are proven, they can be shared or licensed as intellectual property. The value chain structure at MadBiotech takes a self-sufficient and sustainable approach. That way the system is designed, allows for a huge reduction in the process steps as well as provide an increase in worth to the value-added products for consumers and the environment. This is achieved through a farm-to-cafeteria model, which provides fresh, high quality nutritional value foods and functional beverages in the offer. The products are grown and made locally (on-site) and can be replicated at other spaces to meet local consumer demands for health conscious fast-food solutions. This is offer is provided in repurposed shipping containers that use cutting-edge technologies designed to facilitate the companies needs and can operate on a local and global scale (franchise).

1 to 10 staff

Mecconti Labs Sp. Z O.O

Mecconti is one of the leading European providers for high-quality unique products specially designed for microbiology and quality control. Our products are sold through a network of national distributors world-wide. Our portfolio features over 700 Lyophilised Reference Organisms. Mecconti also specializes in the production of hygiene control products widely used in food, cosmetics, or pharmaceutical industry. Sound interesting? Want to join our group of distributors? Contact us. We always look forward to a partnership to expand our business.

1 to 10 staff

Polgen Machejko Sp. K

The POLGEN company started its operations in 1997 in Łódź as a two-person civil partnership of Mariusz Kwiatkowski and Paweł Machejko. In 2007 it was transformed into a limited liability company, and a year later into a limited partnership. The company specializes in the sale of plastics, laboratory equipment and reagents, mainly for scientific and diagnostic laboratories in the field of molecular biology, immunology, cell culture and biobanking. POLGEN cooperates with many prestigious business partners from around the world, known and appreciated in the industry. POLGEN has a Quality Management System certificate in accordance with the PN-EN ISO 9001: 2015 standard and a certificate in accordance with the PN-EN ISO 13485: 2016 standard. The Quality Management System ensures high-quality implementation of trade in laboratory equipment based on efficient management and treatment of customers in accordance with their expectations, and thus providing them with maximum satisfaction from our cooperation.

11 to 50 staff

Quantum Innovations

Quantum was designed to create technologies that solve concrete problems in cardiac surgery, cardiology and respiratory medicine. The primary objective of Quantum devices is to increase the safety of invasive procedures performed in worldwide cardiac surgical centers. First, we focus on highest volume procedures because supporting these will have the most significant impact on population health. We identify critical problems in medical procedures and therapy processes. We design the solution, organize specialist teams, and conduct the projects. Quantum uses scientific methodology to analyze and monitor the global market, population status, public health dynamics, progress in medicines, therapy guidelines, and incoming technologies. Quantum cooperates with universities, laboratories, medical device manufactures, patent attorneys, and venture and seed funds.

1 to 10 staff

Relvo

Acting in accordance with our values: quality and partner relationships rich in trust, we implement our sales policy in Poland and through distributors in several European countries.

1 to 10 staff

Sky Way Biolab

SkyWay Biolab jest firmą prywatną prowadzącą również działalność badawczo – rozwojową. Nasza działalność skupia się na usługach i rozwiązaniach B+R. Oferujemy naukowcom szeroki wybór odczynników i testów z zakresu toksykologii, wirusologii i biologii molekularnej. Zapraszamy do współpracy oferując możliwość wykonywania badań zleconych, a także wspólnej realizacji projektów naukowo-wdrożeniowych.

1 to 10 staff

Allegen

We are the company that deal in the sport in the area of supporting the sportsmen and clubs in optimal decisions based on the genetics research.

1 to 10 staff

Cellis

At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth. Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.

11 to 50 staff

Polish Stem Cells Bank Pbkm Famicord Group

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK. In 2014 PBKM also provides services of production of advanced medical products (ATMP), based on mesenchymal stem cells acquired from voluntary donors. In terms of the number of newly acquired samples Famicord Group is number 1 bank in Europe and one of the largest in terms of total inventory of banked units.

201 to 500 staff

Ctt Centrum Transferu Technologii Gumed Technology Transfer Office Mug

Do głównych zadań Centrum Transferu Technologii należy wspieranie transferu wiedzy i osiągnięć naukowych oraz ich promocja wśród organizacji gospodarczych w zakresie komercjalizacji. Powyższe zadnie realizowane jest poprzez: • identyfikację innowacyjnych rozwiązań powstających na GUMed, • kompleksową ochronę praw własności intelektualnej, • obsługę administracyjną procesu ochrony i korzystania z praw własności intelektualnej GUMed we współpracy z rzecznikiem patentowym, • prowadzenie baz danych o realizowanych projektach, • analiza potencjału rynkowego prowadzonych projektów oraz wyników badań, rekomendacja w przedmiocie ich ochrony, • opracowanie fiszek projektowych wynalazków powstałych w GUMed obejmujących innowacyjne rozwiązania, • promowanie oferty w zakresie innowacyjnych rozwiązań podczas targów, konferencji biznesowych oraz bezpośrednich spotkań z potencjalnymi odbiorcami technologii, • identyfikacja potencjalnych partnerów biznesowych zainteresowanych współpracą przy komercjalizacji lub też licencjonowaniem technologii opracowanych przez naukowców GUMed, • budowanie sieci kontaktów z przemysłem, nawiązywanie i formalizacja kontaktów przedsiębiorców z naukowcami, • udział w negocjacjach, przygotowanie i nadzór nad wykonaniem umów związanych z komercjalizacją, współpraca z Centrami Transferu Technologii, Parkami Naukowo-Technologicznymi i spółkami celowymi oraz innymi powiązanym podmiotami w zakresie komercjalizacji oraz działań proinnowacyjnych, • współpraca z podmiotami zewnętrznymi w zakresie działalności innowacyjnej i podejmowania wspólnych inicjatyw badawczych, w tym budowanie relacji pomiędzy przedstawicielami biznesu a pracownikami i zespołami naukowymi Uniwersytetu.

1 to 10 staff

Genevet

Ustalamy Profil DNA psa, a także jego domniemanych rodziców, na podstawie sekwencji krótkich tandemowych powtórzeń. Badanie wykonujemy na materiale biologicznym w postaci wymazu z pyska psa. Analizie podawanych jest 21 markerów DNA według rekomendacji Międzynarodowego Towarzystwa Genetyki Zwierząt (ISAG). Raz wykonane badanie jest ważne przez całe życie psa i może posłużyć w przyszłości do potwierdzania jego pochodzenia oraz potomstwa. Więcej informacji na

1 to 10 staff

Structural Biology Core Facility

In SBCF we provide services helping scientists to solve the structure of the protein of interest. We help you to obtain your crystals by setting and monitoring the crystallization process at a nano-liter scale. We can also prepare the refinement screening or set the experiment in anaerobic conditions. The list of our services you can find here. On the other hand for cryo-EM samples, our staff is dedicated to share their knowledge by teaching users how to use vitrification robot. We also help with preparing samples for negative staining imaging or SPA. Most importantly we can also provide our users with individualized tailor-made solutions covering the entire macromolecule structure determination pipeline from the experiment design to structure solving.

1 to 10 staff

Bio-Mar Diagnostics

Since 2001 Bio-Mar Diagnostyka has been distributing medical devices for "in vitro" diagnostics to both business and individual customers. It is an authorized representative of leading manufacturers such as Aesku.Diagnostics, Mediwiss Analytic GmbH, Institut Virion \ Serion GmbH, Spinreact, Biotecnica, Teco GmbH, Diamond Diagnostics CORP and Seramun Diagnostica GmbH. Our mission is based on the belief that diagnosis is the first and most important element of disease monitoring, prevention and treatment. That is why BIO-MAR Diagnostyka has been offering its clients not only the highest quality products for 20 years, but also professional consulting in the field of diagnostic services based on many years of experience. The BIO-MAR Diagnostyka team consists of professionals for whom giving customers a sense of security is a priority in this profession.

11 to 50 staff

Cellis

Cellis is an organization that gathers leading scientists in the field of nanotechnology, oncology and molecular biology to work together on integrated therapeutic and diagnostic solutions and to complete the innovative IP portfolio. Company Intellectual Property is protected with PCT patent applications. New patent applications are pending.

11 to 50 staff

Pikralida

Pikralida is a biotechnology company that integrates research and development of innovative therapies (R&D) with Contract Research Organization (CRO) services. As a clinical-stage company, we focus on both proprietary drug development and partnered pharmaceutical research, ensuring a diversified approach that drives innovation and commercial potential. Our mission is to build a high-value portfolio of projects, ultimately leading to future licensing or strategic partnerships for global market introduction. Our flagship development program is centered around PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor with broad therapeutic potential. We are advancing a pipeline of novel applications, with initial clinical-stage programs targeting: 🧠 Neuroprotection (stroke) – therapies designed to minimize long-term neurological damage and improve patient outcomes in ischemic stroke and brain injuries. Snakebite envenoming – innovative pre-hospital treatment solutions, including an oral therapy designed to improve accessibility and survival rates in snakebite cases. Beyond these priority projects, Pikralida maintains an expanding pipeline of preclinical and early-stage programs, exploring additional indications such as diabetic retinopathy and other high-impact therapeutic areas. In addition to our own R&D pipeline, Pikralida operates as a specialized CRO, offering tailored research and development services to biotech and pharmaceutical companies. Our expertise spans across formulation development and pharmaceutical analysis Founded in Poland | Global ambitions | Hybrid business model | Clinical-stage company

11 to 50 staff

Terrabio

Terrabio będzie pierwszym na rynku rolno-spożywczym mobilnym analizatorem genetycznym. Analizator obecnie jest na etapie badań i rozwoju. Urządzenie, nad którym pracuje zespół Terrabio, będzie autonomicznie wykonywać amplifikację, detekcję i interpretację wyników w oparciu o autorski system identyfikacji genetycznej. Wykorzystanie systemu diagnostycznego umożliwi przeprowadzanie badań z obszaru rolnictwa i bezpieczeństwa żywności poprzez szybką identyfikację patogenów czy mutacji genetycznych. Dzięki urządzeniu Terrabio użytkownik w przyszłości otrzyma półilościowy wynik obecności patogenów próbce w ciągu zaledwie 15-35 minut. Obecnie rolnicy zmuszeni są czekać nawet 14 dni na wynik testu zrealizowanego przy użyciu wysoce precyzyjnych metod genetycznych.

1 to 10 staff

Xanto Sp. Z O.O

Xanto Sp. z o.o, headquartered in Gdynia, Poland, is an entity established to implement a project for the commercialization of xanthohumol, consisting in the dissemination of this natural compound with extraordinary properties, practically unavailable to the consumer today. The key factor in this process is access to industrial quantities of xanthohumol at a price that allows the substance to be used in the final product so that its price is acceptable to the consumer. The Company produces xanthohumol using a unique worldwide patented method for manufacturing xanthohumol of the highest purity using an extraction method. The method ensures obtaining the desired substance in quantities and at a price unprecedented on the market.

1 to 10 staff

Agram S.A

1 to 10 staff

Bioceum

We are a supplier of innovative solutions for food production and support for human health, we advise on production and modern biotechnological solutions. For the sake of human health, modern agricultural production will limit the scope of impact on the environment and exclude in practical applications substances considered harmful or likely to have a negative impact on human health, and will reduce the emission of harmful gases into the atmosphere. For the sake of human health, modern agricultural production will limit the scope of impact on the environment and exclude in practical applications substances considered harmful or likely to have a negative impact on human health, and will reduce the emission of harmful gases into the atmosphere. W trosce o zdrowie ludzi nowoczesna produkcja rolnicza ograniczy zakres oddziaływania na środowisko i wykluczy w praktycznych zastosowaniach substancje uznane za szkodliwe lub mogące mieć negatywny wpływ na zdrowie człowieka oraz zmniejszy emisję szkodliwych gazów do atmosfery. In the interests of the health of modern people agricultural products will limit the scope of the impact on the environment, and in practical applications exclude substances that may be harmful or may have a negative impact on human health and reduces emissions to the atmosphere. W trosce o zdrowie współczesnych ludzi produkty rolne ograniczą zakres oddziaływania na środowisko, a w praktycznych zastosowaniach wykluczą substancje, które mogą być szkodliwe lub mogą mieć negatywny wpływ na zdrowie ludzi i zmniejszać emisje do atmosfery. The advisory solutions offered together with the service will prevent threats to the environment as well as animal and human health resulting from microbes and climate protection, based on the offered alternative production technologies based on products harvest from nature.

1 to 10 staff

Medical Inventi S.A

Medical Inventi S.A. to spółka biotechnologiczna założona w 2015 jako inicjatywa środowiska akademickiego Uniwersytetu Medycznego w Lublinie oraz prywatnego kapitału, w celu komercjalizacji badań naukowych wdrażanych na potrzeby profilaktyki i ochrony zdrowia ludzkiego. Portfolio produktowe Spółki obejmuje biomateriał kościozastępczy stosowany w ortopedii pod marką FlexiOss® i stomatologii pod marką FlexiOss®Dent. Wyrób dostępny jest również jako FlexiOss®Vet do zastosowań weterynaryjnych.

1 to 10 staff

Poltiss

11 to 50 staff

Genoscope

Genoscope to firma biotechnologiczna specjalizująca się w produkcji kosmeceutyków i nutraceutyków opartych na COLOSTRUM – naturalnej substancji bogatej w ponad 250 bioaktywnych związków, aminokwasów i czynników wzrostu. Naszą misją jest wspieranie zdrowia i regeneracji organizmu w sposób zgodny z biologią człowieka. Stosujemy rygorystyczne procedury zgodne z międzynarodowymi standardami jakości i bezpieczeństwa: GMP, ISO 22716:2007, ISO 9001:2015, ISO 14001:2015, ISO 13485:2016, HACCP, HALAL oraz IFS Food. Genoscope to dziś marka obecna w ponad 13 aptek w Polsce oraz w ponad 100 krajach na świecie i 6 kontynentach — Azji, Europie, Ameryce Północnej i Południowej, Afryce i Australii. Wierzymy, że przyszłość medycyny i pielęgnacji leży w mądrym wykorzystaniu siły natury. Genoscope is a biotechnology company specializing in the production of cosmeceuticals and nutraceuticals based on COLOSTRUM – a natural substance rich in over 250 bioactive compounds, amino acids, and growth factors. Our mission is to support human health and regeneration in harmony with the biology of the body. We follow strict procedures compliant with international quality and safety standards: GMP, ISO 22716:2007, ISO 9001:2015, ISO 14001:2015, ISO 13485:2016, HACCP, HALAL, and IFS Food. Today, Genoscope is a global brand present in over 13 pharmacies in Poland and in more than 100 countries across six continents — Asia, Europe, North and South America, Africa, and Australia. We believe that the future of medicine and skincare lies in the intelligent use of nature’s power.

11 to 50 staff

Biovetika

Our technology is a platform for producing cheap and effective vaccines against Gram-negative bacteria. An innovative method of combining bacterial components into proteins allows to maintain the full LPS structure. This leads to a more complete response of the immune system and broadens the spectrum of action of the vaccine against many bacterial strains.

1 to 10 staff

Implon Laboratories Ltd

Biotechnology

1 to 10 staff

Koatum

Koatum is a MedTech startup that developed a medical implant coating technology for dental and orthopaedic implants. Koatum prevents inflammation and accelerates bone integration, for a faster, painless recovery. Technology provides opportunity to coat any materials which could not be coated with plasma sputtering due to the high temperatures involved. An inert first layer is ensuring perfect formation between implant and coating. Upper layers, made from hydroxyapatite without the intense heat used in plasma coating, remain bioactive and durable. Technology also provides the ability to implement drug delivery systems. With Koatum technology surgeon can design a customised coating solution tailored to the patient’s needs.

1 to 10 staff

Unlock Project

15 partners from 7 EU countries work together to transform waste from the poultry industry into bio-based products for agricultural applications. The UNLOCK project, funded by the Bio-based Industries Joint Undertaking (BBI JU), aims at designing economically and environmentally sustainable innovative value chains to create a feather based bio-economy. In the course for the four-years project, the feathers will be valorised through four different processes, from mechanical treatment to steam explosion, microbial fermentaion or chemical hydrolysis, depending on the type of end products desired. The bio-based products generated will be tailored to the needs of the agriculture sector, with the creation of seed trays, nonwoven geotextiles, mulch films and hydroponic foams. Futhermore, the keratin contained in those innovative materials will bring additional environmental benefits at the end of the product’s life: keratin-based materials are targeted to be zero waste and allow for controlled biodegradability, while also enriching soils with organic nitrogen. The UNLOCK project is lead by the CIDETEC Foundation. It receives funding from the @EU_H2020 Research & Innovation Programme granted by @BBI2020 under grant agreement nº 101023306. It officially started on 1st May 2021 and will run until April 2025. Consortium members: CIDETEC Foundation (ES) ŁUKASIEWICZ Research Network-Institute of Biopolymers and Chemical Fibres (PL) Asociación de Investigación de Materiales Plásticos (ES) RISE Processum AB (SE) General Hydroponic Europe (FR) Bioextrax AB (SE) Bio-Mi društvo sa ograničenom odgovornoču (HR) NUEVAS TECNOLOGIAS PARA EL DESARROLO DE PACKAGING Y PRODUCTOS AGROALIMENTARIOS CON COMPONENTE PLÁSTICA (ES) FARRELLY & MITCHELL (IE) Organic Waste Systems nv (BE) INKOA SISTEMAS (ES) Associació Comarcal Urgell d'Ajuda al Minusvàlid (ES) Fundacja UNIMOS (PL) Greenovate! Europe EEIG (BE) CEDROB S.A.(PL)

51 to 200 staff

Proteon Pharmaceuticals

Proteon Pharmaceuticals S.A. uses precision biology for microbiome modulation to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. PROTEON's products improve the economic efficiency in livestock farming and aquaculture, increasing environmental sustainability with natural products that also enhance animal welfare.

51 to 200 staff

Pure Biologics

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis. The company is implementing a project titled "Development of a bispecific antibody fragment for the simultaneous targeting of cancer and recruitment of immune system cells [PHASE II]", co-financed by the European Funds for the Modern Economy 2021-2027 (FENG) under action 01.01 SMART Pathways – R&D module of the FENG Program. Agreement No. FENG.01.01-IP.01-1008/23-00 dated 26.09.2024. Project cost: 5 848 PLN Funding amount: 2 924 PLN Project Subject: The subject of the project is R&D work in the area of innovative medical solutions and the implementation of innovations at a global level. Project Objective: A phase 0 clinical trial in patients with solid tumors, which will confirm the mechanism of action and, consequently, the anti-cancer activity of PBA-0405 in the complex microenvironment of human tumors. The goal is to demonstrate the efficacy of the drug under development in human tumors in a phase 0 clinical trial. Phase II tasks: Development work, including continuation of stability testing and phase O clinical trials – patient studies. Project implementation period: 01.01.2024 – 15.11.2025 Contact: info@purebiologics.com | inwestor@purebiologics.com | recruitment@purebiologics.com

51 to 200 staff

Real Research

Our mission is to transform the way people do LifeScience. Our first goal is to shift the entire 2D cell cultures into 3D. To do so we have created our first product, LifeGel. LifeGel is a protein based hydrogel for 3D cell cultures. Batch-to-batch repeatibility, growth factor pure, ready to perform the angiogenesis tests and highly scalable are only few of many LifeGels’ advantages. 3D cell cultures are finally made easy thanks to ready to use LifeGels plate. We believe you have the right to expect the highest quality because your research matters.

1 to 10 staff

Rebread

Bread-waste-to-value startup from Poland which provides biotechnology solutions to upcycling surplus bread into functional food and beverage consumer products, contributing to a more sustainable food system. Participant of the following programs: EIT Food Accelerator Network and ICEX Rising Up in Spain. Want to support or invest in Rebread? Contact: bartlomiej@rebread.com.

1 to 10 staff

Biodose.Net

Growth, knowledge, and curiosity are the values that guide us in our quest for innovative solutions for animal and human wellbeing. Our deep exploration and understanding of nature and its laws inspire us immensely as we journey through the world of biotechnology. Through extensive trials and research, we have developed a portfolio of well-tested products that reduce the use of antibiotics and coccidiostats in the livestock industry. Additionally, we support the health and wellbeing of companion animals with our postbiotic solutions, ensuring the best and holistic care. We are dedicated to sharing nutritional expertise with our clients and partners to enhance breeding and economic outcomes as safe as possible. Moreover, we're committed to sharing insights with the LinkedIn community, fostering industry cooperation and advancement. Join us on this journey of innovation!

11 to 50 staff

Ebi - European Biomedical Institute

European Biomedical Institute (EBI) is a Contract Research Organization (CRO) specializing in comprehensive biocompatibility and chemistry testing for medical devices, performed fully in-house and in compliance with ISO 10993 standards. We are: ISO 17025 accredited GLP certified Compliant with US FDA 21 CFR Part 58 With over 20 years of experience, EBI supports medical device manufacturers by optimizing testing strategies, helping reduce unnecessary costs while ensuring regulatory compliance. Our services cover: Chemical characterization, extractables & leachables (E&L) 🧪 Full ISO 10993 biocompatibility testing (in vitro, in vivo) 🧫 Microbiology and sterility testing 🧴 Cleaning, disinfection, and sterilization validations Packaging validation Toxicology and risk assessments Biological Evaluation Plans (BEP), Reports (BER), and Risk Assessments (BRA) EBI combines scientific expertise, regulatory know-how, and advanced laboratory capabilities to deliver accurate, timely, and cost-effective results. We serve customers across Europe and the U.S, providing expert consultation and personalized support at every stage of the testing process.

51 to 200 staff

Graso Biotech

GRASO BIOTECH jest polską rodzinną firmą z siedzibą w Starogardzie Gdańskim. Firma zajmuje się produkcją podłoży mikrobiologicznych i dystrybucją produktów potrzebnych do wyposażenia laboratoriów diagnostycznych. GRASO jest największym producentem pożywek mikrobiologicznych we wschodniej Europie, a w swojej ofercie posiada ponad 600 rodzajów podłoży. Pragniemy pomóc laboratoriom w dostosowaniu do zmieniających się warunków rynku, dzięki dostarczaniu im szerokiego spektrum produktów, przygotowanych zgodnie z aktualną wiedzą naukową i wymogami prawnymi.

51 to 200 staff